Drug intelligence / Profile preview

amprenavir + efavirenz + abacavir + nelfinavir + ritonavir

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

A combination antiretroviral therapy regimen consisting of amprenavir (protease inhibitor), efavirenz (non-nucleoside reverse transcriptase inhibitor), abacavir (nucleoside reverse transcriptase inhibitor), nelfinavir (protease inhibitor), and ritonavir (protease inhibitor). This combination was studied in clinical trials for HIV-1 infected patients with virologic failure on previous regimens, particularly in the Adult AIDS Clinical Trials Group protocols.

Targets

Human immunodeficiency virus type 1 reverse transcriptaseHLA-B*57:01 (Human leukocyte antigen B*57:01)CYP3A7 (Cytochrome P450 3A7)PR (Progesterone receptor)

Beyond the preview

Go deeper on amprenavir + efavirenz + abacavir + nelfinavir + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amprenavir + efavirenz + abacavir + nelfinavir + ritonavir.

Explore the full profile